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tory cells including eosinophils, lymphocytes, and mast 
cells1）. Guidelines for the treatment of asthma devel-
oped in Japan, Europe, and the United States place im-
portance on the control of airway inflammation, and in-
haled corticosteroids play a central role. However, 
some patients have inadequate control of symptoms 
despite the use of anti-inflammatory agents, such as 
moderate to even high doses of inhaled corticosteroids 
and antileukotriene agents. Thus, these guidelines em-
phasize not only anti-inflammatory agents but also di-
lation of the obstructed airways using bronchodila-
INTRODUCTION
Bronchial asthma is considered to be a chronic aller-
gic inflammatory disease characterized by airway hy-
perresponsiveness and infiltration of airway inflamma-
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SUMMARY
Background：Bronchial asthma is considered to be a chronic airway inflammatory disease, and inhaled 
corticosteroids play a central role in controlling airway inflammation. In some patients, however, it is diffi-
cult to control symptoms despite the use of moderate to high doses of inhaled corticosteroids. Long-acting 
inhaled b2-agonists have recently become available and reconsidered as a controller.
Objectives：To examine whether combination of an inhaled corticosteroid and an oral b2-agonist can im-
prove symptoms in patients with moderate bronchial asthma whose airway obstructive symptoms cannot 
be relieved sufficiently by inhaled corticosteroids alone.
Methods：Of outpatients in our hospital with moderate bronchial asthma （step 3） given beclomethasone 
at a daily dose of 800 mg, whose peak expiratory flow rate in the early morning was 70％ or less of the pre-
dicted value, 12 patients were enrolled in the study who showed at least 12.5％ improvement in the forced 
expiratory volume in one second （FEV1.0） after inhalation of 20 mg procaterol （Meptin Air from Otsuka 
Pharma. Co.） for 15 minutes. Procaterol tablets （Meptin tablets, 50 mg from Otsuka Pharma. Co.） were ad-
ministered in the morning and before bed for 4 weeks, and change in the peak expiratory flow rate, subjec-
tive symptoms, respiratory function, and the number of puffs of the b2-agonist were evaluated.
Results：The peak expiratory flow rate, FEV1.0, forced vital capacity （％FVC），and airway hyperre-
sponsiveness improved after coadministration of oral procaterol and beclomethasone. 
Conclusions：The oral b2-agonist in combination with an inhaled corticosteroid might improve asthma 
symptoms better than inhaled corticosteroids alone.
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tors1）. Among the bronchodilators, b2-agonists are 
often used as inhalants because of the quick onset of 
action, promotion of clearance of airway secretions by 
ciliary movement, enhancement of airway clearance, 
and ease of use2）. However, b2-agonists have only mod-
est anti-inflammatory effects2）. Moreover, disadvantag-
es of preexisting short-acting inhaled b2-agonists have 
been highlighted, including the lack of long-term bene-
fits3）, airway hyperresponsiveness enhanced4） and 
symptoms destabilized and the risk of asthma death 
increased by regular use of the inhalants alone2）. 
Therefore, appropriate use of b2-agonists has been 
pressed, and a series of new long-acting inhaled b2-ag-
onists5, 6） and b2-agonist patch formulations7） were de-
veloped. They have a prolonged bronchodilating effect 
and thus are highly effective in relieving asthma symp-
toms at night and in the early morning, preventing 
morning dip, and improving quality of life （QOL）．
Long-acting inhaled b2-agonists in combination with 
inhaled corticosteroids were shown to be effective in 
improving symptoms 8〜11）, and more effective than leu-
kotriene receptor antagonists 12,13）. Thus, the guidelines 
came to recommend these long-acting b2-agonists as a 
controller. Oral b2-agonists such as procaterol, tu-
lobuterol, and clenbuterol have high selectivity for b2-
receptors and a long duration of action. Unlike inhaled 
agents, long-term regular use of oral agents has been 
reported to rarely cause serious adverse reactions, and 
bronchodilating effect is less likely to wane2）. These 
agents do not require special inhalation techniques and 
offer ease of use and appear to be useful as a control-
ler. However, there are few studies which examined 
the effect of a combination of an oral b2-agonist and an 
inhaled corticosteroid except for bambuterol. Thus, we 
examined whether a combination of an inhaled corti-
costeroid and an oral b2-agonist is effective in improv-
ing symptoms in patients with moderate bronchial 
asthma whose airway obstruction are not well im-
proved by inhaled corticosteroids alone.
METHODS
Among outpatients with moderate （step 3） bronchial 
asthma given beclomethasone at a daily dose of 800 mg 
for at least 2 weeks and had a morning peak expirato-
ry flow rate of 70％ or less of the predicted value, pa-
tients who showed at least 12.5％ improvement of 
FEV1.0 15 minutes after inhalation of 20 mg of procaterol 
（Meptin Air from Otsuka Pharma. Co.） were enrolled 
in this study. Patients who regularly used oral or in-
haled b2-agonists were excluded. Patients who used 
systemic corticosteroids during a 2-week run-in peri-
od were also excluded. Table 1 shows patients baseline 
characteristics. Procaterol tablets （Meptin tablets, 
50 mg from Otsuka Pharma. Co.） were orally adminis-
tered in the morning and at bedtime for 4 weeks. The 
peak expiratory flow rate and respiratory functions 
（FVC, FEV1.0, and FEV1.0％） in the early morning and 
at bedtime and change in airway hyperresponsiveness 
were measured 1 week before treatment and at 4 
weeks. Peak expiratory flow rates were measured us-
ing a Mini-Wright, and the highest of three readings 
was recorded. Respiratory functions were evaluated 
with an AutoSpiro （Minato）. For assessment of airway 
hyperresponsiveness, acetylcholine threshold values 
were used as described in the standard methods estab-
lished by the Japanese Society of Allergology 1）. Briefly, 
a DeVilbiss 646 nebulizer driven by compressed air at 
5 L/min was used, and patients were instructed to in-
hale diluted acetylcholine solutions at concentrations of 
313 to 20,000 mg/mL stepwise for 5 minutes each. The 
FEV1.0 was measured immediately after inhalation, and 
the concentration of acetylcholine required to reduce 
the value by at least 20％ from baseline served as the 
threshold of acetylcholine. Student’s t-test was used 
for statistical analysis. P values of less than 0.05 were 
considered a statistical significance.
RESULTS
1． Change in the morning peak expiratory flow 
rate after addition of procaterol 
The mean morning peak expiratory flow rate was 
348.5±37.2 L/min 1 week before procaterol treatment 
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Table 1　Patient Baseline Characteristics
Sex： 9 males, 3 femal
Age： 58.8±3.4 years
Duration of morbidity： 10.4±2.4 years
Improvement of FEV1.0
after inhalation of procaterol： 26.6±4.2％
Actual peak flow/predicted peak flow： 66.7±4.8％
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and 367.8±40.4 L/min at 4 weeks （P＝0.06）, indicat-
ing a tendency toward improvement （Figure 1）. The 
morning peak expiratory flow expressed as a percent-
age of the predicted value significantly increased to 
70.5±5.4％ （P＜0.05） after concomitant use of the 
b2-agonist compared with the baseline of 66.7±4.6％ 
（Figure 2）. The mean improvement was 5.4±3.1％ 
（P＝0.11）.
2．Change in FEV1.0
There was a significant improvement in the mean 
FEV1.0 from 1.73±0.20 L a week before treatment to 
2.05±0.21 L at 4 weeks （P＜0.01） （Figure 3）．
3．Change in％FVC
There was an improvement in the mean％FVC from 
77.2±8.5％ a week before treatment to 83.5±6.31％ 
at 4 weeks （P＜0.05） （Figure 4）．
4．Change in threshold of acetylcholine
The mean threshold of acetylcholine significantly in-
creased from 1275.0±53.0 mg/mL before treatment to 
2435.0±234.0 mg/mL at 4 weeks （P＜0.01） （Figure 
5）．
DISCUSSION
Onset of action of b2-agonists is quicker than other 
bronchodilators, in particular, inhalers of short-acting 
b2-agonists can relax the airway smooth muscle in a 
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Figure 1　 Change in morning peak expiratory flow rates 
after addition of procaterol （100 mg/day） in 
patients with bronchial asthma under inhaled 
corticosteroids
Figure 3　 Change in FEV1.0 after addition of procaterol 
（100 mg/day） in patients with bronchial asthma 
under inhaled corticosteroids
Figure 2　 Change in peak expiratory flow expressed as a 
percentage of the predicted value after addition 
of procaterol （100 mg/day） in patients with 
bronchial asthma under inhaled corticosteroids 
Figure 4　 Change in ％FVC after addition of procaterol 
（100 mg/day） in patients with bronchial asthma 
under inhaled corticosteroids
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few minutes after the drug reached the airways. The 
drugs bind to b2-receptors in the airway smooth mus-
cle and activate adenylate cyclase which increases 
cAMP, resulting in bronchodilation14）. Inhaled b2-ago-
nists also enhance ciliary movement, enhances excre-
tion of airway secreta and increase airway clearance14）. 
b2-agonitsts including isoproterenol once provoked an 
issue of cardiovascular side effects because they also 
stimulate b1-receptors to the same extent. Since then, 
the primary focus of developing b2-agonists was to im-
prove selectivity for b2-receptors in order to reduce 
cardiovascular side effects. Currently available short-
acting b2-agonists have high selectivity for b2-recep-
tors, proving the problem was almost cleared14）. Never-
theless, these short-acting b2-agonists still have other 
issues to be concerned with. The onset of action is rap-
id yet the duration of action is short, and their effec-
tiveness as a reliever of asthma attacks has been con-
firmed, yet it was pointed out that symptoms become 
destabilized to the extent even leading to asthma 
deaths because the bronchodilating effect decreases 
over the long time when they are used on a regular 
basis, and they enhance airway hyperresponsiveness4）. 
In particular, a well known report is a paper revealing 
association between increased asthma deaths and in-
creased use of short-acting b2-agonists in New Zea-
land in 1980s and it was followed by many other re-
ports suggesting relationship between increased 
asthma deaths and increased use of short-acting b2-
agonists across the world. To overcome this issue, 
long-acting inhaled b2-agonists were developed. These 
new agonists and patch formulations developed in Ja-
pan have replaced the conventional short-acting ago-
nists, and their position as a controller has been estab-
lished1）. Such a long duration of action can be 
ascribable to increased liposolubility of side chains of 
b2-agonists, which enables longer retention of the drug 
in tissues16） and improved sustained release system ex-
tended to 12−24 hours for the patch formulation17）. 
These long-acting b2-agonists are effective in relieving 
symptoms at night and early morning and exercise-in-
duced asthma and in improving QOL. It has been dem-
onstrated that their bronchodilating effect rarely 
decreases even over a long time18, 19） airway hyperre-
sponsiveness rarely enhances20） and they have little ef-
fect on cardiovascular system21） However, anti-inflam-
matory effect of b2-agonists is too weak to be a cure 
for asthma in general. Therefore, a combination with 
anti-inflammatory drugs is essential and various guide-
lines also place an importance on this point. Given the 
results of recently published SMART study that even 
monotherapy of long-acting b2-agonists increased 
asthma deaths and the study was terminated22）, anti-
inflammatory drugs should be combined. Coadministra-
tion of long-acting b2-agonists as a controller and in-
haled steroids or antileukotriene antagonists exhibited 
superior effect to monotherapy. It is not recommended 
either to switch from combination of inhaled steroids 
and b2-agonists into b2-agonists monotherapy even af-
ter symptoms are well controlled23, 24）. Thus, any b2-ag-
onist should be combined with inhaled steroids after 
all. On the other hand, procaterol, clenbuterol, and tu-
lobuterol have high selectivity for b2-receptors and 
longer duration of action for 8 to 10 hours than other 
short-acting b2-agonits and are recommended as a 
controller1）．
Unlike inhalants, regular use of oral b2-agonists over 
the long time rarely decreases brochodilating effect, 
enhances hyrereactivity or cause serious adverse ef-
fect such as asthma death2） Moreover, oral b2-agonists 
are characterized by much easier use compared to in-
halants which require special devices and techniques. 
It is easy and simple to just swallow tablets for pa-
tients with decreased lung function and the elderly pa-
tients who have difficulties in inhaling drugs. Com-
pared to patch formulations, oral formulation have 
some advantages：no need to strip off a thin seal or 
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Figure 5　 Change in a irway hyperrespons iveness 
（threshold of acetylcholine） after addition of 
procaterol （100 mg/day） in patients with 
bronchial asthma under inhaled corticosteroids
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they cause no skin reaction on the affected site25）. Oral 
formulations are systemic and should not be used in 
patients with hyperthyroidism. Caution is needed 
when they are prescribed to patients with underlying 
cardiovascular disease, hypertension or diabetes1）. 
They appear to be useful controllers if these issues are 
taken care of. In fact, oral b2-agonists have still been 
widely used in Japan although there were few studies 
on the combination of inhaled steroids and oral b2-ago-
nists. We often experience that oral b2-agonists are ef-
fective in patients whose airway obstructive symptoms 
cannot be controlled by a moderate to high dose of 
800 mg/day beclomethasone as anti-inflammatory ther-
apy. Therefore, we examined the effect of oral pro-
caterol combined with corticosteroids. Oral procaterol 
improved FEV1.0 significantly after combined use. 
Morning peak flow rate and a peak flow predicted val-
ue were improved by approx. 5％ without a significant 
difference. Probably because there were considerable 
variations in peak flow rates due to different age and 
physique and the number of 12 patients is too small to 
have a significant difference. Overall, there was a ten-
dency toward improvememt and it appeared that a 
combination was superior to monotherapy of inhaled 
steroids in patients with morning dip. FVC also im-
proved because occlusive symptoms improved, which 
suggests increased gas volume inhaled into the whole 
lungs and a possibility of improving inhalation efficien-
cy by combination with inhaled steroids. It is needed 
to compare the effect of coadministration of an inhaled 
steroid with an oral b2-agonist and combination of a 
long-acting inhaled b2-agonist available in other coun-
tries and an inhaled steroid. If oral formulations are 
demonstrated to improve inhalation efficiency through 
dilation of peripheral airways more than inhalants do, 
use of oral b2-agonists will be recommended more 
without reservation. Further studies are expected. On 
the other hand, bronchial hypersensitivity appear to be 
improved given increased threshold of acetylcholine. 
This can be ascribable to antagonism of procaterol 
against constriction of the airway smooth muscle. It 
seems that oral b2-agonists do not aggravate airway 
hypersensitivity unlike short-acting b2-agonists if in-
haled steroids are combined. Long-acting b2-agonists 
have been demonstrated not to aggravate airway hy-
perresponsiveness compared to short-acting b2-ago-
nists20, 26）. There was no significant difference in change 
in airway hyperresponsiveness in a study between 
patch and oral formulations of tulobuterol in childhood 
asthma and it suggests that long-acting b2-agonists 
can be used as a controller when being combined with 
corticosteroids27）. In this study, oral procaterol com-
bined with inhaled steroids did not aggravate but rath-
er improved airway hyperreactivity. This might be a 
character of oral procaterol but it is too early to com-
ment on that before the long-term effect of oral pro-
caterol is confirmed. It is safe to say that oral procater-
ol can be used as a controller because it does not 
aggravate airway hypersensitivity as short-acting b2-
agonists do. The benefits of oral b2-agonists distinctive 
from long-acting b2-agonists and patch formulations 
include ease of use and certain bronchodilation of pe-
ripheral airways attained by systemic effect of oral 
medication28）. It will be necessary to demonstrate that 
oral b2-agonists or some of them have significant ad-
vantages over inhaled b2-agonists including combina-
tion therapy with inhaled steroids. Oral b2-agonists re-
quire caution to patients with thyroid disease, 
cardiovascular disesase, diabetes, etc., given the side 
effects caused by systemic administration, and there-
fore, it is needed to determine criteria to clarify whom 
oral b2-agonists are indicated for. In addition, new oral 
b2-agonists should be a once-a-day formulation with a 
longer duration of action for 12 to 24 hours rathen than 
the current 8−10 hours and have much fewer cardio-
vascular side effects, and others such as tremor and 
headache to be used as a controller.
CONCLUSION
The study suggests that oral b2-agonists combined 
with inhaled steroids can improve asthmatic symptoms 
which are not well controlled by inhaled steroids alone, 
and be an effective controller like long-acting inhaled 
b2-agonists and patch formulations.
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